New research presented at a major European lung disease conference suggests that semaglutide, the drug behind Ozempic and Wegovy, may be linked to substantially fewer asthma attacks and COPD flare-ups ...

Growing evidence linked GLP-1 drugs to a reduced risk of exacerbations of two types of chronic airways disease: asthma and chronic obstructive pulmonary disease (COPD). Based on real-world records ...

Patients with asthma or COPD who used semaglutide for type 2 diabetes experienced significant reductions in their ...

Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. It was also associated with about 20% fewer COPD flare-ups. Researchers ...

Semaglutide and Asthma? The popular GLP-1 diabetes and weight-loss injection may be linked to fewer asthma attacks and COPD flare-ups.

There is renewed hope for patients struggling with asthma and chronic obstructive pulmonary disease.

Semaglutide could be tied to nearly 40% fewer asthma attacks, according to medical record studies. — dpa Semaglutide-based ...

GSK plc (LSE/NYSE: GSK) today announced new effectiveness data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus ...

AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales.

The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research ...

COPD can cause persistent cough, wheezing, and breathlessness, but early diagnosis and treatment can help slow its ...

Smoking can damage far more than the lungs. People who smoke or previously smoked have a higher risk of several long-term ...